单位：[1]AstraZeneca, IMED Asia, Shanghai, Peoples R China[2]Dizal Jiangsu Pharmaceut Co Ltd, Shanghai, Peoples R China[3]Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China广东省人民医院[4]Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China广东省人民医院[5]AstraZeneca, Res Dev Informat, Shanghai, Peoples R China[6]AstraZeneca, China Dev Unit, Shanghai, Peoples R China[7]Chinese Acad Med Sci, Dept Resp Med, Peking Union Med Coll Hosp, Beijing, Peoples R China[8]Canc Hosp Jilin Prov, Dept Oncol, Changchun, Jilin, Peoples R China[9]Huazhong Univ Sci & Technol, Tongji Med Coll, Canc Ctr Tongji Hosp, Wuhan, Hubei, Peoples R China肿瘤科华中科技大学同济医学院附属同济医院[10]Zhengzhou Univ, Affiliated Canc Hosp, Resp Dept Internal Med, Zhengzhou, Henan, Peoples R China河南省肿瘤医院[11]Chinese Acad Med Sci, Beijing Key Lab Clin Study Anticancer Mol Targete, Canc Hosp, Dept Med Oncol,Natl Canc Ctr, Beijing, Peoples R China[12]Peking Union Med Coll, Beijing, Peoples R China[13]Sichuan Univ, West China Sch Clin Med, West China Hosp, Dept Thorac Oncol,Canc Ctr, Chengdu, Sichuan, Peoples R China四川大学华西医院[14]Jiangsu Canc Hosp, Dept Oncol, Nanjing, Jiangsu, Peoples R China[15]Tangdu Hosp, Dept Oncol, Tangdu Comprehens Canc Ctr, Xian, Shaanxi, Peoples R China[16]AstraZeneca, Cambridge, England[17]Tongji Univ, Shanghai Pulm Hosp, Dept Oncol, Shanghai, Peoples R China
Hu Min,Wu Yi-Long,Zhu Xuehua,et al.Identification of osimertinib resistance mechanisms in Chinese NSCLC patients: Analysis from AURA17 trial[J].JOURNAL OF CLINICAL ONCOLOGY.2018,36(15):doi:10.1200/JCO.2018.36.15_suppl.9077.
APA：
Hu, Min,Wu, Yi-Long,Zhu, Xuehua,Sun, Yun,Lu, Xuesong...&Zhou, Caicun.(2018).Identification of osimertinib resistance mechanisms in Chinese NSCLC patients: Analysis from AURA17 trial.JOURNAL OF CLINICAL ONCOLOGY,36,(15)
MLA：
Hu, Min,et al."Identification of osimertinib resistance mechanisms in Chinese NSCLC patients: Analysis from AURA17 trial".JOURNAL OF CLINICAL ONCOLOGY 36..15(2018)
医学